UV Flu Technologies Receives Large UV-400 Air Purifier Order Directly Targeting Residential Marketplace

UV Flu Technologies (OTCBB:UVFT) announces that the company has received an order for 100 UV-400 air purifying units from Semper Fi, a Long Island based distribution company which primarily markets to residential consumers.

The Distributor has advised that they are actively adding representatives to cover sales leads encompassing the Tri-State area. In response, the Company has ensured that an ample quantity of units to satisfy initial sales needs have been priority diverted for immediate shipment to the client.

“This order is significant because our product was principally designed for the commercial marketplace,” said Jack Lennon, President of UV Flu Technologies. “Our UV-400 has been laboratory tested and proven to offer highly effective airborne bacteria-killing capabilities that will provide Semper Fi with a product truly superior to anything else currently in the marketplace.”

Mr. Lennon continues, “We want to also note that in the residential market we have received feedback from the field where certain individuals have reported a dramatic difference in their respiratory issues in as little as 2-3 hours from starting their UV-400 at home. In the past month alone, we have received testimonials from consumers indicating that individuals with sleep disorders due to snoring have seen significant improvement while operating the unit in their bedroom at night. The Company makes no claims in this area, but is planning to follow up on these reports in order to determine if further study or future development in this area is warranted.”

Further details regarding the Company’s business, financial reports and agreements are filed as part of the Company’s continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission’s (“SEC”) EDGAR database.

UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality (“IAQ”) industry sector. The Company manufactures the ViraTech UV-400, which utilizes high-intensity germicidal ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria at rates exceeding 99.2% on a first-pass basis. ViraTech UV-400 is a Class II medical device and is available without a prescription.

UV Flu Technologies, Inc.
411 Main Street, Bldg. 5
Yarmouthport, MA 02675
1 877 358-5455

Geaux IR Services
1 888 355 8838
investors@uvflutech.com

This release was published on openPR.